Edition:
United Kingdom

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

16.03USD
3:55pm BST
Change (% chg)

$0.09 (+0.56%)
Prev Close
$15.94
Open
$16.04
Day's High
$16.12
Day's Low
$15.88
Volume
136,579
Avg. Vol
1,700,309
52-wk High
$17.45
52-wk Low
$5.28

Latest Key Developments (Source: Significant Developments)

Endo Lifts Temporary Stay Of FDA Litigation After Launch Of Bulk-Compounded Vasopressin
Wednesday, 15 Aug 2018 

Aug 15 (Reuters) - Endo International PLC ::ENDO LIFTS TEMPORARY STAY OF FDA LITIGATION FOLLOWING THE LAUNCH OF A BULK-COMPOUNDED VASOPRESSIN PRODUCT BY A SECTION 503B OUTSOURCING FACILITY.ENDO INTERNATIONAL PLC - LITIGATION ALSO SEEKS IMMEDIATE REMOVAL OF VASOPRESSIN FROM FDA'S CATEGORY 1 NOMINATIONS LIST.  Full Article

Nevakar And Endo Enter Into Exclusive Licensing Agreement
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Endo International PLC ::NEVAKAR AND ENDO ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR MULTIPLE 505(B)(2) INJECTABLE PRODUCTS.NEVAKAR - ENTERED LICENSING AGREEMENT WITH ENDO INTERNATIONAL'S UNIT FOR DEVELOPMENT OF DIFFERENTIATED, STERILE INJECTABLE PRODUCTS IN U.S. & CANADA.NEVAKAR - PURSUANT TO AGREEMENT, CO TO DEVELOP & SEEK U.S. FDA APPROVAL FOR PRODUCTS TO BE DEVELOPED UNDER AGREEMENT WITH ENDO'S UNIT.NEVAKAR - ENDO'S PAR PHARMACEUTICAL STERILE PRODUCTS DIVISION TO LAUNCH, DISTRIBUTE PRODUCTS DEVELOPED UNDER AGREEMENT UPON FDA APPROVAL.  Full Article

Endo Q2 GAAP Loss Per Share $0.23 From Continuing Operations
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Endo International PLC ::ENDO REPORTS SECOND-QUARTER 2018 FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.76 FROM CONTINUING OPERATIONS.Q2 GAAP LOSS PER SHARE $0.23 FROM CONTINUING OPERATIONS.Q2 REVENUE $715 MILLION VERSUS I/B/E/S VIEW $678.3 MILLION.Q2 EARNINGS PER SHARE VIEW $0.54 -- THOMSON REUTERS I/B/E/S.COMPANY RAISES 2018 FINANCIAL GUIDANCE.SEES 2018 TOTAL REVENUES TO BE BETWEEN $2.75 BILLION AND $2.85 BILLION.SEES 2018 ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS TO BE BETWEEN $2.50 AND $2.60.PHASE 3 TRIALS FOR COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (CCH) EXPECTED TO HAVE TOP-LINE RESULTS IN FOURTH-QUARTER 2018.  Full Article

Bioprojet, Endo Announce Agreement For Paladin Labs To Commercialize Pitolisant In Canada
Wednesday, 25 Jul 2018 

July 25 (Reuters) - Endo International PLC ::BIOPROJET AND ENDO JOINTLY ANNOUNCE AGREEMENT FOR PALADIN LABS INC. TO COMMERCIALIZE PITOLISANT IN CANADA.ENDO INTERNATIONAL - PALADIN WILL BE RESPONSIBLE FOR REGISTRATION DISTRIBUTION, SALES, MARKETING, MEDICAL AFFAIRS IN CONNECTION WITH PITOLISANT.ENDO INTERNATIONAL PLC - BIOPROJET WILL BE RESPONSIBLE FOR SUPPLYING PITOLISANT TO PALADIN.  Full Article

Endo, Bayer defeat Custopharm appeal over Aveed patents
Friday, 13 Jul 2018 

July 13 (Reuters) - Endo, bayer defeat appeal by custopharm over validity of patents related to testosterone replacement therapy aveed -- u.s. Court ruling:.  Full Article

Lannett Acquires Portfolio Of Generic Products From Endo International
Monday, 7 May 2018 

May 7 (Reuters) - Lannett Company Inc ::LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL.LANNETT COMPANY INC - TRANSACTION INCLUDES 23 APPROVED AND 1 PENDING DRUG PRODUCT APPLICATIONS, PRIMARILY ORAL SOLUTIONS.LANNETT - ACQUIRED 23 APPROVED AND ONE PENDING DRUG PRODUCT APPLICATIONS FROM UNIT OF ENDO FOR UPFRONT PAYMENT PLUS FUTURE MILESTONE PAYMENTS.LANNETT - EXPECT TO BEGIN LAUNCHING PRODUCTS, AFTER TRANSFER ACTIVITIES ARE COMPLETED, REGULATORY FILINGS MADE, ESTIMATED TO BE IN H2 2019.  Full Article

Endo International Receives Paragraph IV Notification On Vasostrict
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Endo International PLC ::ENDO RECEIVES PARAGRAPH IV NOTIFICATION ON VASOSTRICT.ENDO INTERNATIONAL-LETTER CONTAINS CERTIFICATIONS ALLEGING INVALIDITY,NON-INFRINGEMENT FOR 5 PATENTS CO LISTED IN APPROVED DRUG PRODUCTS FOR VASOSTRICT.ENDO IS ASSESSING DETAILS OF NOTICE LETTER AND FORMULATING ITS LEGAL STRATEGY.ENDO INTERNATIONAL - NOTICE LETTER ADVISING THAT EAGLE PHARMACEUTICALS SUBMITTED ANDA TO FDA SEEKING APPROVAL TO MARKET GENERIC VERSION OF VASOSTRICT.  Full Article

Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA
Monday, 16 Apr 2018 

April 16 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA.EAGLE PHARMACEUTICALS INC - PRODUCT IS GENERIC VERSION OF ENDO INTERNATIONAL PLC'S ORIGINAL VASOSTRICT FORMULATION.  Full Article

Endo International says No Proceedings Have Currently Been Initiated Against EPI As Result Of Subpoena
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Endo International Plc ::ENDO INTERNATIONAL - TO ENDO'S KNOWLEDGE, NO PROCEEDINGS HAVE CURRENTLY BEEN INITIATED AGAINST EPI AS A RESULT OF SUBPOENA - SEC FILING.  Full Article

Endo Comments On U.S. Attorney's Office Grand Jury Subpoena Relating To Products Containing Oxymorphone
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Endo International Plc ::ENDO COMMENTS ON UNITED STATES ATTORNEY'S OFFICE GRAND JURY SUBPOENA RELATING TO PRODUCTS CONTAINING OXYMORPHONE.ENDO INTERNATIONAL - UNIT ENDO PHARMACEUTICALS RECEIVED GRAND JURY SUBPOENA FROM UNITED STATES ATTORNEY'S OFFICE FOR SOUTHERN DISTRICT OF FLORIDA.ENDO - ‍SUBPOENA REQUESTS DISTRIBUTION,THIRD PARTY AGREEMENTS,DOCUMENTS ON INTERACTIONS WITH GOVERNMENT. AGENCIES RELATED TO PRODUCTS CONTAINING OXYMORPHONE​.  Full Article

UPDATE 2-U.S. FDA proposes restricting compounding of 3 drug substances

Aug 27 The U.S. Food and Drug Administration on Monday proposed excluding three substances from a list of ingredients that could be used to manufacture compounded medications in bulk for use by hospitals and doctors' offices.